Trek Financial LLC Has $1.14 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Trek Financial LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 53.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,358 shares of the company’s stock after purchasing an additional 2,572 shares during the quarter. Trek Financial LLC’s holdings in Johnson & Johnson were worth $1,140,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Sierra Capital LLC raised its holdings in shares of Johnson & Johnson by 0.6% during the 4th quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock worth $1,773,000 after buying an additional 61 shares in the last quarter. MTM Investment Management LLC grew its position in Johnson & Johnson by 0.5% during the 1st quarter. MTM Investment Management LLC now owns 11,283 shares of the company’s stock worth $1,749,000 after acquiring an additional 61 shares during the last quarter. OneAscent Financial Services LLC grew its position in Johnson & Johnson by 3.3% during the 1st quarter. OneAscent Financial Services LLC now owns 1,986 shares of the company’s stock worth $308,000 after acquiring an additional 63 shares during the last quarter. Well Done LLC grew its position in Johnson & Johnson by 0.4% during the 1st quarter. Well Done LLC now owns 15,584 shares of the company’s stock worth $2,415,000 after acquiring an additional 64 shares during the last quarter. Finally, FIDELIS iM LLC grew its position in shares of Johnson & Johnson by 3.1% in the 4th quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock valued at $374,000 after buying an additional 64 shares during the last quarter. 68.40% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 0.3 %

Shares of JNJ stock opened at $160.56 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04. The company has a market capitalization of $417.29 billion, a PE ratio of 32.50, a price-to-earnings-growth ratio of 3.47 and a beta of 0.54. The business’s fifty day moving average is $166.11 and its 200 day moving average is $161.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The business had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. During the same quarter last year, the business posted $2.59 earnings per share. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. On average, equities research analysts anticipate that Johnson & Johnson will post 10.03 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were given a dividend of $1.19 per share. The ex-dividend date was Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a yield of 2.96%. Johnson & Johnson’s payout ratio is 96.36%.

Analysts Set New Price Targets

JNJ has been the topic of a number of analyst reports. Credit Suisse Group upped their price target on Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, July 21st. Morgan Stanley dropped their price target on Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 31st. Wells Fargo & Company dropped their price target on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a research note on Thursday, August 31st. StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday. Finally, JPMorgan Chase & Co. increased their price objective on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $170.65.

Insider Buying and Selling at Johnson & Johnson

In other news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares in the company, valued at $15,092,484. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares in the company, valued at $15,092,484. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Insiders have sold 47,163 shares of company stock worth $7,928,856 over the last 90 days. Corporate insiders own 0.20% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.